Nutritional Anti-Inflammatories in the Treatment and Prevention of Type 2 Diabetes Mellitus and the Metabolic Syndrome

Overweight and obesity is epidemic across the developed world and prevalence in Australia is amongst the highest, with obesity alone costing the health system an estimated $837million[1]. Approximately 40% of Australians are overweight, undoubtedly adding to these costs and burden on the healthcare system[1]. Obesity and overweight comprise some of the key features of the Metabolic Syndrome (MetS), which is defined as central obesity plus any two of the following: raised triglycerides>1.7mmol/L, decreased high density lipoprotein cholesterol (HDL)5.6mmol/L or diagnosis of type 2 diabetes mellitus (T2DM).

Source: Diabetes Research and Clinical Practice - February 17, 2017 Category: Endocrinology Authors: Lea Merone Tags: Review Source Type: research